Biogen Inc. ( BIIB ) and Boston Scientific ( BSX ) have both reported their earnings today, showcasing their recent first-quarter performances. Among their notable achievements are the remarkable success of Biogen's Alzheimer's drug Leqembi and Boston Scientific's strides in medical technology. Biogen Surpasses Expectations with Strong First-Quarter Performance Biogen Inc. surpassed market expectations for first-quarter profit, reporting adjusted earnings of $3.67 per share, outpacing analysts' forecasts of $3.44. The company's robust performance was buoyed by the growing traction of its new Alzheimer's drug, Leqembi, and significant cost-cutting measures. Shares of Biogen surged as much as 5.5% following the earnings announcement, marking the company's most substantial intraday gain since January 2023. 👉 Check Out Video --> BIIB Price Analysis The success of Leqembi, developed in collaboration with Japan's Eisai Co., is particularly notable. Sale